Geopolitical uncertainty delaying customer approvals
War and geopolitical tensions are prolonging regulatory approvals for end products, pushing back commercialization timelines by 6-12 months.
SHREEGANESHREMEDIES / Q4-FY26 / risks
Keep the risk register visible.
Shree Ganesh Remedies · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Domestic pricing pressure on generic products
Increasing competition in domestic generic products is compressing realizations and margins, though the company is shifting focus away from this segment.
Lumpy revenue from graphene projects
Analyst raised concern that graphene projects may be lumpy; management acknowledged but did not provide specific revenue projections, indicating uncertainty.
Raw material price volatility
Crude oil price fluctuations impact solvent costs, affecting procurement decisions and margins across the portfolio.